SCHEMBL15073262

SCHEMBL15073262

CCc1cc(F)ccc1OC(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR4 Q5NUL3 1/20 0.43
▸ MPO P05164 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ SLC6A4 P31645 5/20 0.40
▸ KCNH2 Q12809 5/20 0.40
▸ HTR2A P28223 2/20 0.40
▸ EPHX2 P34913 1/20 0.39
▸ SLC6A2 P23975 1/20 0.38
▸ SLC6A3 Q01959 1/20 0.38
▸ GPR3 P46089 1/20 0.37
▸ TMEM97 Q5BJF2 3/20 0.36
▸ SIGMAR1 Q99720 3/20 0.36
▸ P2RX7 Q99572 1/20 0.36
▸ PDE2A O00408 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ ADORA2A P29274 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8429890 0.85 EPHX2 (0.39) FFAR4SLC6A4KCNH2HTR2AEPHX2
SCHEMBL23047223 0.83 HTR2A (0.37) FFAR4KDM4ESLC6A4KCNH2HTR2A
SCHEMBL16956735 0.81 KDM4E (0.40) KDM4ESLC6A4KCNH2HTR2AEPHX2
SCHEMBL16958568 0.81 FFAR4 (0.43) FFAR4MPOSLC6A4KCNH2EPHX2
SCHEMBL24459258 0.81 MPO (0.41) FFAR4MPOSLC6A4KCNH2HTR2A
SCHEMBL18543262 0.81 MPO (0.44) FFAR4MPOSLC6A4KCNH2EPHX2
SCHEMBL18588991 0.81 SLC6A4 (0.59) MPOSLC6A4KCNH2HTR2ASLC6A2
SCHEMBL17449715 0.81 KCNH2 (0.41) FFAR4MPOSLC6A4KCNH2SLC6A2
SCHEMBL30785121 0.80 KDM4E (0.53) KDM4ESLC6A4KCNH2HTR2ASLC6A2
SCHEMBL321697 0.80 KDM4E (0.53) KDM4ESLC6A4KCNH2HTR2ASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2794611-B1 PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS GILEAD SCIENCES INC (US) 2017-10-11 — — EP disclosed
US-9518000-B2 Bicyclo [2.2.1] acid GPR120 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2016-12-13 — — US disclosed
US-20160016880-A1 BICYCLO [2.2.1] ACID GPR120 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2016-01-21 — — US disclosed
WO-2013096681-A1 PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS GILEAD SCIENCES, INC. (US) 2013-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160016880-A1 BICYCLO [2.2.1] ACID GPR120 MODULATORS GPR180, GPR88, GPBAR1 FFAR4 54/4885MPO 4811/4885KDM4E 4189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback